Alector | MedPath

Alector Announces Strategic Priorities for 2025, Highlights Neurodegenerative Disease Programs

4 months ago

• Alector anticipates topline data from the Phase 3 INFRONT-3 trial of latozinemab for frontotemporal dementia with a granulin gene mutation (FTD-GRN) by Q4 2025. • Enrollment in the Phase 2 PROGRESS-AD trial of AL101/GSK4527226 for early Alzheimer's disease is expected to complete in mid-2025, with 75% of participants enrolled. • Alector is advancing its preclinical pipeline, utilizing the Alector Brain Carrier (ABC) technology to enhance therapeutic delivery for neurodegenerative diseases. • The company's cash reserves of $457.2 million as of September 30, 2024, are projected to sustain operations through 2026, supporting ongoing clinical and research programs.

Alector Presents Baseline Data from INVOKE-2 Phase 2 Trial of AL002 for Early Alzheimer's Disease

10 months ago

• Alector presented baseline characteristics from the INVOKE-2 Phase 2 trial of AL002, a novel TREM2 agonist, at the Alzheimer's Association International Conference (AAIC) 2024. • The INVOKE-2 trial enrolled 381 participants with early Alzheimer's disease, showing a median age of 71 years and confirming amyloid positivity in all participants. • Treatment-emergent brain MRI changes (ARIA) were observed, with higher incidence and severity in APOE e4 homozygous carriers, leading to their early discontinuation from the trial. • Results from the INVOKE-2 trial are expected in the fourth quarter of 2024, with a long-term extension study ongoing to assess the long-term effects of AL002.

FDA Grants Breakthrough Therapy Designation to Latozinemab for FTD-GRN

a year ago

• The FDA has granted Breakthrough Therapy Designation to latozinemab for frontotemporal dementia with a progranulin gene mutation (FTD-GRN). • Latozinemab, developed by Alector and GSK, is a monoclonal antibody that elevates progranulin levels by blocking sortilin. • The designation was based on Phase 2 clinical trial data, indicating substantial improvement over available therapies for this rare, rapidly progressing disease. • Latozinemab is currently in a pivotal Phase 3 study (INFRONT-3), with target enrollment achieved in October 2023.